Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis

• Published in: Frontiers in endocrinology (Lausanne) 2024-01, Vol.14, p.1303238-1303238
• Main Authors: Tan, Luyuan, Wang, Zhaonan, Okoth, Kelvin, Toulis, Konstantinos A, Denniston, Alastair K, Singh, Baldev M, Crowe, Francesca L, Sainsbury, Christopher, Wang, Jingya, Nirantharakumar, Krishnarajah
• Format: Article
• Language: English
• Subjects: Acarbose - therapeutic use; antidiabetic medications; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; diabetic complication; diabetic retinopathy; Diabetic Retinopathy - complications; Diabetic Retinopathy - etiology; Dipeptidyl-Peptidase IV Inhibitors - pharmacology; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Endocrinology; Glucagon-Like Peptide 1 - therapeutic use; Humans; Hypoglycemic Agents - pharmacology; Insulin - therapeutic use; meta-review; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; type 2 diabetes
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2023.1303238

Diabetic retinopathy (DR) is the most frequent complication of type 2 diabetes and remains the leading cause of preventable blindness. Current clinical decisions regarding the administration of antidiabetic drugs do not sufficiently incorporate the risk of DR due to the inconclusive evidence from preceding meta-analyses. This umbrella review aimed to systematically evaluate the effects of antidiabetic drugs on DR in people with type 2 diabetes. A systematic literature search was undertaken in Medline, Embase, and the Cochrane Library (from inception till 17th May 2022) without language restrictions to identify systematic reviews and meta-analyses of randomized controlled trials or longitudinal studies that examined the association between antidiabetic drugs and DR in people with type 2 diabetes. Two authors independently extracted data and assessed the quality of included studies using the AMSTAR-2 (A MeaSurement Tool to Assess Systematic Reviews) checklist, and evidence assessment was performed using the GRADE (Grading of recommendations, Assessment, Development and Evaluation). Random-effects models were applied to calculate relative risk (RR) or odds ratios (OR) with 95% confidence intervals (CI). This study was registered with PROSPERO (CRD42022332052). With trial evidence from 11 systematic reviews and meta-analyses, we found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), or dipeptidyl peptidase-4 inhibitors (DPP-4i) was not statistically associated with the risk of DR, compared to either placebo (RR: GLP-1 RA, 0.98, 0.89-1.08; SGLT-2i, 1.00, 95% CI 0.79-1.27; DPP-4i, 1.17, 0.99-1.39) or other antidiabetic drugs. Compared to other antidiabetic drugs, meglitinides (0.34, 0.01-8.25), SGLT-2i (0.73, 0.10-5.16), thiazolidinediones (0.92, 0.67-1.26), metformin (1.15, 0.81-1.63), sulphonylureas (1.24, 0.93-1.65), and acarbose (4.21, 0.44-40.43) were not statistically associated with the risk of DR. With evidence from longitudinal studies only, insulin was found to have a higher risk of DR than other antidiabetic drugs (OR: 2.47, 95% CI: 2.04-2.99). Our results indicate that antidiabetic drugs are generally safe to prescribe regarding the risk of DR among people with type 2 diabetes. Further robust and large-scale trials investigating the effects of insulin, meglitinides, and acarbose on DR are warranted. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=332052, identif